Gudrun Dandekar

Gudrun Dandekar

Auto-generated profile, based on publicly available information

Gudrun Dandekar

Department for Functional Materials in Medicine and Dentistry, University Hospital Würzburg, Würzburg, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2019 in JCI Insight
Verified
Journal Article
Closed access
LWLars Wallstabe
Lars Wallstabe
CGClaudia Göttlich
Claudia Göttlich
LNLena C. Nelke
Lena C. Nelke
JKJohanna Kühnemundt
Johanna Kühnemundt
TSThomas Schwarz
Thomas Schwarz
MHMichael Hudecek
Michael Hudecek
Solid tumors impose immunologic and physical barriers to the efficacy of chimeric antigen receptor (CAR) T cell therapy that are not reflected in conventional preclinical testing against singularized tumor cells in 2-dimensional culture. Here, we established microphysiologic three-dimensional (3D) lung and breast cancer models that resemble architectural and phenotypical features of primary tumors and evaluated the antitumor function of receptor tyrosine kinase–like orphan receptor 1–specific (ROR1-specific) CAR T cells. 3D tumors were established from A549 (non–small cell lung cancer) and MDA-MB-231 (triple-negative breast cancer) cell lines on a biological scaffold with intact basement membrane (BM) under static and dynamic culture conditions, which resulted in progressively increasing cell mass and invasive growth phenotype (dynamic > static; MDA-MB-231 > A549). Treatment with ROR1-CAR T cells conferred potent antitumor effects. In dynamic culture, CAR T cells actively entered arterial medium flow and adhered to and infiltrated the tumor mass. ROR1-CAR T cells penetrated deep into tumor tissue and eliminated multiple layers of tumor cells located above and below the BM. The microphysiologic 3D tumor models developed in this study are standardized, scalable test systems that can be used either in conjunction with or in lieu of animal testing to interrogate the antitumor function of CAR T cells and to obtain proof of concept for their safety and efficacy before clinical application.

18 June 2025 in Lung Cancer
Verified
Journal Article
Open access
SCSamantha A.W. Crouch
Samantha A.W. Crouch
MPMatthias Peindl
Matthias Peindl
EBElena Bencúrová
Elena Bencúrová
ACAylin Caliskan
Aylin Caliskan
Thomas DandekarThomas Dandekar
Thomas Dandekar
TBTim Breitenbach
Tim Breitenbach
Detailed analysis of RNAseq datasets combined with signaling networksin physiologically relevant models are fundamental steps in the fight against drug resistance. For this purpose, we compare RNAseq data of different responsive KRASG12C-mutant cell lines, H358 and HCC44, to illustrate distinct resistance scenarios against a KRAS-inhibitor. We apply the following steps to investigate this: (I) Analysis of variance shows several differentially expressed marker genes for non-small cell lung cancer (NSCLC) and confirms HCC44 cells to be more aggressive. (II) Protein network analysis of key players of resistance reveals upregulation of Dachshund homolog 1 (DACH1) only in treated H358 cells. (III) A systematic analysis of NSCLC with a semi-quantitative signaling network predicts several protein targets counter-acting the KRASG12C-mutation, including DACH1. (IV) We show correlations between the expression level of these genes and resulting survival outcomes using TCGA data from patients. (V) We validate key signature genes by quantitative PCR in H358 cells. Our study identifies DACH1 as marker for resistance from RNAseq data of a 3D tissue NSCLC model validated with patient survival data. We predictmost promising candidates for combination therapies in silico.

23 October 2026 in npj Systems Biology and Applications
Verified
Journal Article
Open access
PDF file
MAMaryam Almasi
Maryam Almasi
JPJesús Guillermo Nieves Pereira
Jesús Guillermo Nieves Pereira
TDThomas Dandekar
Thomas Dandekar
GDGudrun Dandekar
Gudrun Dandekar
JBJohannes Balkenhol
Johannes Balkenhol
Pancreatic ductal adenocarcinoma (PDAC) develops chemoresistance through dynamic cell-state transitions, yet the regulatory network architecture governing drug-tolerant states remains poorly characterised, because static expression snapshots cannot capture how interaction topology evolves along treatment-induced trajectories. We established a 3D PANC-1 tissue model on decellularised porcine intestinal matrix, which reaches patient-like proliferation indices and tissue-niche-specific drug responses, and performed single-cell RNA sequencing across four conditions: control, gemcitabine (GEM), TGF-β1, and their combination. Coupling pseudotime trajectory inference to dynamic protein–protein interaction network analysis, we tracked betweenness centrality continuously across cell-state transitions rather than comparing discrete states. GEM survivors engaged a proliferative programme (E2F1, CDK1, AURKA, TPX2, TOP2A, BIRC5), whereas TGF-β1 induced an independent EMT attractor (SPOCK1, MBOAT2, COL5A1, THBS1, FN1). Where the two converged, an emergent bottleneck appeared: CDK1 betweenness centrality spiked selectively, restrained by CDKN1A (p21) and WEE1, defining an S-phase-persistence state enriched for GEM survivors. Cross-examination in a PDAC atlas of 726,107 cells from 231 patients showed 8.7-fold metastatic enrichment of triple-positive cells. This framework, linking controlled 3D tissue experimentation, single-cell systems analysis and clinical-scale patient data, is applicable to drug resistance across cancer types.